Advertisement

Clinical Pharmacokinetics

, Volume 8, Issue 3, pp 233–252 | Cite as

Clinical Pharmacokinetics of the Newer Benzodiazepines

  • David J. Greenblatt
  • Marcia Divoll
  • Darrell R. Abernethy
  • Hermann R. Ochs
  • Richard I. Shader
Article

Summary

New benzodiazepine derivatives continue to be developed and introduced into clinical use. The pharmacokinetic properties of these newer drugs can best be understood by their categorisation according to range of elimination half-life and pathway of metabolism (oxidation versus conjugation). Clobazam and halazepam are long half-life (and therefore accumulating) anxiolytics metabolised by oxidation. Alprazolam and clotiazepam also are oxidised compounds but have short to intermediate half-life values and therefore produce considerably less accumulation. Temazepam and lormetazepam are hypnotic agents with intermediate half-lives but metabolised by conjugation. The most unique of the newer benzodiazepines are the ultra-short half-life (oxidised) compounds midazolam, triazolam and brotizolam, which are essentially non-accumulating during multiple dosage.

Keywords

Clinical Pharmacology Cimetidine Alprazolam Triazolam Oxazepam 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abernethy, D.R.; Greenblatt, D.J.; Divoll, M.; Ameer, B. and Shader, R.I.: Differential effect of cimetidine on drug oxidation (antipyrine, diazepam) versus conjugation (acetaminophen, lorazepam): Prevention of acetaminophen toxicity by cimetidine. Journal of Pharmacology and Experimental Therapeutics (In press. 1982a).Google Scholar
  2. Abernethy, D.R.; Greenblatt, D.J.; Divoll, M.; Arendt, R.; Ochs, H.R. and Shader, R.I.: Impairment of diazepam metabolism by low-dose estrogen oral contraceptive steroids. New England Journal of Medicine 306: 791–792 (1982b).PubMedCrossRefGoogle Scholar
  3. Abernethy, D.R.; Greenblatt, D.J.; Divoll, M.; Harmatz, J.S. and Shader, R.I.: Alterations in drug distribution and clearance due to obesity. Journal of Pharmacology and Ex and Experimental Therapeutics 217: 681–685 (1981).Google Scholar
  4. Abernethy, D.R.; Greenblatt, D.J.; Divoll, M.; Moschitto, L.J.; Harmatz, J.S. and Shader, R.I.: Interaction of cimetidine with the triazolo benzodiazepines alprazolam and triazolam. Psychopharmacology (In press, 1982c).Google Scholar
  5. Adams, W.J.: Specific and sensitive high performance liquid Chromatographic determination of alprazolam or triazolam. Analytical Letters 12: 657–671 (1979).CrossRefGoogle Scholar
  6. Adams, W.J.: Rykerl, U.M. and Bombardt, P.A.: High performance liquid Chromatographic determination of triazolam in human serum. Analytical Letters 13: 149–161 (1980).CrossRefGoogle Scholar
  7. Allen, M.D.: Greenblatt, D.J.; Harmatz, J.S. and Shader, R.I.: Dcsmcthyl-diazepam kinetics in the elderly after oral prazepam. Clinical Pharmacology and Therapeutics 28: 196–202 (1980).PubMedCrossRefGoogle Scholar
  8. Alloncn, H.: Ziegler, G. and Klotz, U.: Midazolam kinetics. Clinical Pharmacology and Therapeutics 30: 653–661 (1981).CrossRefGoogle Scholar
  9. Arendt, R.: Ochs, H.R. and Greenblatt, D.J.: Electron-capture GLC analysis of the thienodiazepine clotiazepanr. Preliminary pharmacokinetic studies. Arzneimittel-Forschung 32: 453–455 (1982).PubMedGoogle Scholar
  10. Belvedere, G.; Tognoni, G.; Frigerio, A. and Morselli, P.L.: A specific rapid and sensitive method for gas Chromatographie determination of methyl-oxazepam in small samples of blood. Analytical Letters 5: 531–541 (1972).CrossRefGoogle Scholar
  11. Bittencourt, P.; Richens, A.; Toseland, P.A.; Wicks, J.F.C. and Latham, A.N.: Pharmacokinetics of the hypnotic benzodiaze-pine, temazepam. British Journal of Clinical Pharmacology 8: 37s–38s (1979).PubMedCrossRefGoogle Scholar
  12. Brcimcr, D.D.; Jochemsen, R. and von Albert, H.H.: Pharmacokinetics of benzodiazepines. Arzneimittel-Forschung 30: 875–881 (1980).Google Scholar
  13. Brogden, R.N.; Heel, R.C.; Speight, T.M. and Avery, G.S.: Clobazam: A review of its pharmacological properties and therapeutic use in anxiety. Drugs 20: 161–178 (1980).PubMedCrossRefGoogle Scholar
  14. Caccia, S.; Ballabio, M.; Guiso, G. and Zanini, M.G.: Gas-liquid Chromatographie determination of clobazam and N-desmethylclobazam in plasma. Journal of Chromatography 164: 100–105 (1979).PubMedCrossRefGoogle Scholar
  15. Divoll, M. and Greenblatt, D.J.: Plasma concentrations of temazepam, a 3-hydroxy benzodiazepine, determined by electron-capture gas-liquid chromatography. Journal of Chromatography 222: 125–128 (1981).PubMedCrossRefGoogle Scholar
  16. Divoll, M. and Greenblatt, D.J.: Effect of age and sex on lorazepam protein binding. Journal of Pharmacy and Pharmacology 34: 122–124 (1982).PubMedCrossRefGoogle Scholar
  17. Divoll, M.; Greenblatt, D.J.; Ciraulo, D.A.; Puri, S.K.; Ho, I. and Shader, R.I.: Clobazam kinetics: Intrasubject variability and effect of food on absorption. Journal of Clinical Pharmacology 22: 69–73 (1982).PubMedGoogle Scholar
  18. Divoll, M.: Greenblatt, D.J.; Harmatz, J.S. and Shader, R.I.: Effect of age and gender on disposition of temazepam. Journal of Pharmaceutical Sciences 70: 1104–1107 (1981).PubMedCrossRefGoogle Scholar
  19. Eberts, F.S.; Philopoulos, Y.; Reineke, L.M. and Vliek, R.W.: Disposition of 14-C-alprazolam, a new anxiolytic-antidepressant, in man. Pharmacologist 22: 279 (1980).Google Scholar
  20. Eberls, F.S.; Philopoulos, Y.; Reineke, L.M. and Vliek, R.W.: Triazolam disposition. Clinical Pharmacology and Therapeutics 29: 81–93 (1981).CrossRefGoogle Scholar
  21. Fccly, J.; Wilkinson, G.R. and Wood, A.J.J.: Reduction of liver blood flow and propranolol metabolism by cimetidine. New England Journal of Medicine 304: 692–695 (1981).CrossRefGoogle Scholar
  22. Fuccclla, L.M.; Bolcioni, G.; Tamassia, V.; Ferrario, L. and Tog-noni, G.: Human pharmacokinelics and bioavailability of tcmazepam administered in soft gelatin capsules. European Journal of Clinical Pharmacology 12: 383–386 (1977).CrossRefGoogle Scholar
  23. Fuccclla, L.M.; Tosolini, G.; Moro, E. and Tamassia, V.: Study of physiological availability of temazepam in man. International Journal of Clinical Pharmacology, Therapy and Toxicology 6: 303–309 (1972).Google Scholar
  24. George, K.A. and Dundee, J.W.: Relative amnesic actions of di-azeparn, flunitrazepam and lorazepam in man. British Journal of Clinical Pharmacology 4: 45–50 (1977).PubMedCrossRefGoogle Scholar
  25. Greenblatt, D.J.: Electron-capture GLC determination of clobazam and desmcthylclobazam in plasma. Journal of Pharmaceutical Sciences 69: 1351–1352 (1980).PubMedCrossRefGoogle Scholar
  26. Greenblatt, D.J.: Clinical pharmacokinetics of oxazepam and lorazepam. Clinical Pharmacokinetics 6: 89–105 (1981).PubMedCrossRefGoogle Scholar
  27. Greenblatt, D.J.: Allen, M.D.; Harmatz, J.S. and Shader, R.I.: Diazepam disposition determinants. Clinical Pharmacology and Therapeutics 27: 301–312 (1980a).PubMedCrossRefGoogle Scholar
  28. Grecnblatl, D.J.; Allen, M.D.; Locniskar, A.; Harmatz, J.S. and Shader, R.I.: Lorazepam kinetics in the elderly. Clinical Pharmacology and Therapeutics 26: 103–113 (1979a).Google Scholar
  29. Greenblatt, D.J.: Divoll, M.; Abernethy, D.R. and Shader, R.I.: Benzodiazepine hypnotics: Kinetic and therapeutic options. Sleep 5: s18–s27 (1982a).PubMedGoogle Scholar
  30. Grecnblatl, D.J.: Allen, M.D.; MacLaughlin, D.S.; Huffman, D.H.; Harmatz, J.S. and Shader, R.I.: Single- and multiple-dose kinetics of oral lorazepam in humans: The predictability of accumulation. Journal of Pharmacokinetics and Biopharma-ceulics 7: 159–179 (1979b).Google Scholar
  31. Greenblatt, D.J.: Divoll, M.; Abernethy, D.R.; Harmatz, J.S. and Shader, R.I.: Antipyrine kinetics in the elderly: Prediction of age-related changes in benzodiazepine oxidizing capacity. Journal of Pharmacology and Experimental Therapeutics 220: 120–126 (1982c).PubMedGoogle Scholar
  32. Greenblatt, D.J.; Divoll, M.; Abernethy, D.R.; Moschino, L.J.; Smith, R.B. and Shader, R.I.: Alprazolam kinetics in the elderly: Relation to antipyrine disposition. Archives of General Psychiatry (In press, 1982e).Google Scholar
  33. Greenblatt, D.J.; Divoll, M.; Abernethy, D.R.; Moschitto, L.J.; Smith, R.B. and Shader, R.I.: Reduced clearance of triazolam in old age: Relation to antipyrine oxidizing capacity. British Journal of Clinical Pharmacology (In press, 1982f).Google Scholar
  34. Greenblatt, D.J.; Divoll, M.; Harmatz, J.S. and Shader, R.I.: Oxazepam kinetics: Effects of age and sex. Journal of Pharmacology and Experimental Therapeutics 215: 86–91 (1980b).PubMedGoogle Scholar
  35. Greenblatt, D.J.; Divoll, M.; Moschitto, L.J. and Shader, R.I.: Electron-capture gas Chromatographie analysis of the triazo-lobcnzodiazepines alprazolam and triazolam. Journal of Chromatography 225: 202–207 (1981c).PubMedCrossRefGoogle Scholar
  36. Grecnblatl, D.J.; Divoll, M.; Puri, S.K.; Ho, I.; Zinny, M.A. and Shader, R.I.: Reduced single-dose clearance of clobazam in elderly men predicts increased multiple-dose accumulation. Clinical Pharmacokinetics 8: 83–94 (1983).CrossRefGoogle Scholar
  37. Grecnblail, D.J.; Divoll, M.; Puri, S.K.; Ho, I.; Zinny, M.A. and Shader, R.I.: Clobazam kinetics in the elderly. British Journal of Clinical Pharmacology 12: 631–636 (1981b).CrossRefGoogle Scholar
  38. Greenblatt, D.J.; Locniskar, A. and Shader, R.I.: Pilot phar-macokinetic study of brotizolam, a thienodiazepine hypnotic, using electron-capture gas-liquid chromatography. Sleep (In press, 1982g).Google Scholar
  39. Greenblatt, D.J.; Locniskar, A. and Shader, R.I.: Halazepam, another precursor of desmethyldiazepam. Lancet 1: 1358–1359 (1982d).PubMedCrossRefGoogle Scholar
  40. Greenblatt, D.J.; Locniskar, A.; Ochs, H.R. and Lauven, P.M.: Automated gas chromatography for studies of midazolam pharmacokinetics. Anesthesiology 55: 176–179 (1981d).PubMedCrossRefGoogle Scholar
  41. Grcenblatl, D.J.; Sellers, E.M. and Shader, R.I.: Drug disposition in old age. New England Journal of Medicine 306: 1081–1088 (1982b).CrossRefGoogle Scholar
  42. Greenblatt, D.J.; Shader, R.I.; Divoll, M. and Harmatz, J.S.: Benzodiazepines: A summary of pharmacokinetic properties. British Journal of Clinical Pharmacology 11:11s–16s (1981a).PubMedCrossRefGoogle Scholar
  43. Greenblatt, D.J.; Shader, R.I.; MacLeod, S.M. and Sellers, E.M.: Clinical pharmacokinetics of chlordiazepoxide. Clinical Pharmacokinetics 3: 381–394 (1978).PubMedCrossRefGoogle Scholar
  44. Humpel, M.; Illi, V.; Milius, W.; Wendt, H. and Kurowski, M.: The pharmacokinetics and biotransformation of a new benzodiazepine (lormetazepam) in humans. !. Absorption, distribution, elimination, and metabolism of lormetazepam-5-14C. European Journal of Drug Metabolism and Pharmacokinetics 4: 237–243 (1979).PubMedCrossRefGoogle Scholar
  45. Humpel, M.; Nieuweboer, B.; Milius, W.; Hanke, H. and Wendt, H.: Kinetics and biotransformation of lormetazepam. II. Radioimmunologic determinations in plasma and urine of young and elderly subjects: First-pass effect. Clinical Pharmacology and Therapeutics 28: 673–679 (1980).PubMedCrossRefGoogle Scholar
  46. Jochemsen, R. and Breimer, D.D.: Assay of triazolam in plasma by capillary gas chromatography. Journal of Chromatography 223: 438–444 (1981).PubMedCrossRefGoogle Scholar
  47. Jochemsen, R. and Breimer, D.D.: Assay of flunitrazepam, temazepam and desalkyflurazepam in plasma by capillary gas chromatography with electron-capture detection. Journal of Chromatography 227: 199–206 (1982).PubMedCrossRefGoogle Scholar
  48. Kales, A.; Scharf, M.B. and Kales, J.D.: Rebound insomnia: A new clinical syndrome. Science 201: 1039–1041 (1978).PubMedCrossRefGoogle Scholar
  49. Kampf, D.; Huempel, M.; Lerche, U. and Kessel, M.: Effects of uremia and hemodialysis on lormetazepam disposition. Clinical Pharmacology and Therapeutics 30: 77–85 (1981).PubMedCrossRefGoogle Scholar
  50. Kangas, L. and Breimer, D.D.: Clinical pharmacokinetics of niirazepam. Clinical Phartnacokinetics 5: 346–366 (1981).CrossRefGoogle Scholar
  51. Klutz, J.; Kangas, L. and Kanto, J.: Clinical pharmacokinetics of benzodiazepines. Progress in Pharmacology, Vol. 3, No. 3 (Gustav Fisher Verlag Stuttgart and New York 1980).Google Scholar
  52. Klotz, U. and Reimann, I.: Delayed clearance of diazepam due to cimetidine. New England Journal of Medicine 302: 1012–1014 (1980).PubMedCrossRefGoogle Scholar
  53. Kothary, S.P.; Brown, A.C.D.; Pandit, U.A.; Samra, S.K. and Pandit, S.K.: Time course of antirecall effect of diazepam and lorazepam following oral administration. Anesthesiology 55: 641–644 (1981).PubMedCrossRefGoogle Scholar
  54. Lauven, P.M.; Stoeckel, H. and Schwilden, H.: A microprocessor controlled infusion scheme for midazolam to achieve constant plasma levels. Anaesthetist 31: 15–20 (1982).Google Scholar
  55. MacLeod, S.M.; Sellers, E.M.; Giles, H.G.; Billings, B.J.; Martin, P.R.; Greenblatt, D.J. and Marshman, J.A.: Interaction of disulfiram with benzodiazepines. Clinical Pharmacology and Therapeutics 24: 583–589 (1978).PubMedGoogle Scholar
  56. Mandelli, M.; Tognoni, G. and Garattini, S.: Clinical pharmacokinetics of diazepam. Clinical Pharmacokinetics 3: 72–91 (1978).PubMedCrossRefGoogle Scholar
  57. Miller, M.M.: Evaluation of temazepam as a hypnotic. Phar-macotherapy I: 3–13 (1981).Google Scholar
  58. Murray, T.G.; Chiang, S.T.; Koepke, H.H. and Walker, B.R.: Renal disease, age, and oxazepam kinetics. Clinical Pharmacology and Therapeutics 30: 805–809 (1981).PubMedCrossRefGoogle Scholar
  59. Ochs, H.R. and Greenblatt, D.J.: Interaction of triazolam with ethanol and isoniazid. Clinical Pharmacology and Therapeutics 33: 241 (1983).Google Scholar
  60. Ochs, H.R.; Steinhaus, E.; Locniskar, A.; Knuchel, M. and Green-blatl, D.J.: Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipo-tassium. Klinische Wochenschrift 60: 411–415 (1982).PubMedCrossRefGoogle Scholar
  61. Ochs, H.R.; Greenblatt, D.J.; Kaschell, H.J., Klehr, U.; Divoll, M. and Abernethy, D.R.: Diazepam kinetics in patients with renal insufficiency or hyperthyroidism. British Journal of Clinical Pharmacology 12: 829–832 (1981b).PubMedCrossRefGoogle Scholar
  62. Ochs, H.R.; Greenblatt, D.J.; Roberts, G.-M. and Dengler, H.J.: Diazepam interaction with antituberculosis drugs. Clinical Pharmacology and Therapeutics 29: 671–678 (1981a).PubMedCrossRefGoogle Scholar
  63. Pakes, G.E.; Brogden, R.N.; Heel, R.C.; Speight, T.M. and Avery, G.S.: Triazolam: A review of its pharmacological properties and therapeutic efficacy in patients with insomnia. Drugs 22: 81–110 (1981).PubMedCrossRefGoogle Scholar
  64. Patwardhan, R.V.; Yarborough, G.W.; Desmond, P.V.; Johnson, R.F.; Schenker, S. and Speeg, K.V.: Cimetidine spares the glu-curonidation of lorazepam and oxazepam. Gastroenterology 79: 912–916 (1980).PubMedGoogle Scholar
  65. Pieri, L.; Schaffner, R.; Scherschlicht, R.; Pole, P. and Sepinwall, J.: Pharmacology of midazolam. Arzneimittel-Forschung 31: 2180–2201 (1981).PubMedGoogle Scholar
  66. Puglisi, C.V.; Meyer, J.C.; D’Arconte, L.; Brooks, M.A. and de Silva, J.A.F.: Determination of water soluble imidazo-1,4-benzodiazepines in blood by electron-capture gas-liquid chro-matography and in urine by differential pulse polarography. Journal of Chromatography 145: 81–96 (1978).PubMedCrossRefGoogle Scholar
  67. Riva, R.; Tedeschi, G., Albani, F. and Baruzzi, A.: Quantitative determination of clobazam in the plasma of epileptic patients by gas-liquid chromatography with electron-capture detection. Journal of Chromatography 225: 219–224 (1981).PubMedCrossRefGoogle Scholar
  68. Roberts, R.K.; Wilkinson, G.R.; Branch, R.A. and Schenker, S.: The effects of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (Librium). Gastroenterology 75: 479–485 (1978).PubMedGoogle Scholar
  69. Rupp, W.; Badian, M.; Christ, O.; Hadju, P.; Kulkarni, R.D.; Taeuber, K.; Uihlein, M.; Bender, R. and Vanderbeke, O.: Pharmacokinetics of single and multiple doses of clobazam in humans. British Journal of Clinical Pharmacology 7: 51s–57s (1979).PubMedCrossRefGoogle Scholar
  70. Schwarz, H.J.: Pharmacokinetics and metabolism of temazepam in man and several animal species. British Journal of Clinical Pharmacology 8: 23s–29s (1979).PubMedCrossRefGoogle Scholar
  71. Sellers, E.M.; Giles, H.G.; Greenblatt, D.J. and Naranjo, C.A.: Differential effects on benzodiazepine disposition by disulfiram and ethanol. Arzneimittel-Forschung 30: 882–886 (1980).PubMedGoogle Scholar
  72. Sellers, E.M.; Greenblatt, D.J.; Giles, H.G.; Naranjo, C.A.; Kaplan, H. and MacLeod, S.M.: Chlordiazepoxide and oxazepam disposition in cirrhosis. Clinical Pharmacology and Therapeutics 26: 240–246 (1979).PubMedGoogle Scholar
  73. Sethy, V.H. and Harris, D.W.: Determination of biological activity of alprazolam, triazolam and their metabolites. Journal of Pharmacy and Pharmacology 34: 115–116 (1982).PubMedCrossRefGoogle Scholar
  74. Shader, R.I.; Ciraulo, D.A.; Greenblatt, D.J. and Harmatz, J.S.: Steady-state plasma desmethyldiazepam during long-term clorazepate use: Effect of antacids. Clinical Pharmacology and Therapeutics 31: 180–183 (1982).PubMedCrossRefGoogle Scholar
  75. Shader, R.I.; Greenblatt, D.J.; Harmatz, J.S.; Franke, K. and Koch-Weser, J.: Absorption and disposition of chlordiazepoxide in young and elderly male volunteers. Journal of Clinical Pharmacology 17: 709–718 (1977).PubMedGoogle Scholar
  76. Shader, R.I.; Greenblatt, D.J.; Ciraulo, D.A.; Divoll, M.; Harmatz, J.S. and Georgotas, A.: Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate. Psychopharmacology 75: 193–197 (1981).PubMedCrossRefGoogle Scholar
  77. Shull, H.J.; Wilkinson, G.R.; Johnson, R. and Schenker, S.: Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Annals of Internal Medicine 84: 420–425 (1976).PubMedGoogle Scholar
  78. Smith, M.T.; Eadie, M.J. and Brophy, T.O.: The pharmacokinetics of midazolam in man. European Journal of Clinical Pharmacology 19: 271–278 (1981).PubMedCrossRefGoogle Scholar
  79. Tedeschi, G.; Riva, R. and Baruzzi, A.; Clobazam plasma concentrations: Pharmacokinetic study in healthy volunteers and data in epileptic patients. British Journal of Clinical Pharmacology 11: 619–622 (1981).PubMedCrossRefGoogle Scholar
  80. Vasiliades, J. and Owens, C.: Determination of midazolam in serum by gas chromatography with a nitrogen-selective delecior. Journal of Chromatography 182: 439–444 (1980).PubMedCrossRefGoogle Scholar
  81. Vasiliades, J. and Sahawneh, T.H.: Determination of midazolam by high-performance liquid chromatography. Journal of Chromalography 225: 266–271 (1981).CrossRefGoogle Scholar
  82. Vasiliades, J.V. and Sahawneh, T.: Midazolam determination by gas chromatography, liquid chromatography and gas chro-matography-mass spectrometry. Journal of Chromatography 228: 195–203 (1982).PubMedCrossRefGoogle Scholar
  83. Volz, M.; Christ, O.; Kellner, H.-M.; Kuch, H.; Fehlhaber, H.-W.; Gantz, D.; Hadju, P. and Cavagna, F.: Kinetics and metabolism of clobazam in animals and man. British Journal of Clinical Pharmacology 7: 41s–50s (1979).PubMedCrossRefGoogle Scholar
  84. Vrce, T.B.; Baars, A.M.; Booij, L.H.D. and Driessen, J.J.: Simultaneous determination and pharmacokinetics of midazolam and its hydroxy metabolites in plasma and urine of man and dog by means of high-performance liquid chromatography. Arzneimittel-Forschung 31: 2215–2219 (1981).Google Scholar
  85. Vree, T.B.; Baars, A.M.; Hekster, Y.A. and van der Kleijn, E.: Simultaneous determination of diazepam and its metabolites N-desmethyldiazepam, oxydiazepam and oxazepam in plasma and urine of man and dog by means of high-performance liquid chromatography. Journal of Chromatography 162: 605–614 (1979).PubMedCrossRefGoogle Scholar
  86. Wilkinson, G.R.: The effects of liver disease and aging on the disposition of diazepam, chlordiazepoxide, oxazepam and lorazepam in man. Acta Psychiatrica Scandinavica (Suppl. 274): 56–74 (1978).PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Australasia Pty Ltd. 1983

Authors and Affiliations

  • David J. Greenblatt
    • 1
    • 2
  • Marcia Divoll
    • 1
    • 2
  • Darrell R. Abernethy
    • 1
    • 2
  • Hermann R. Ochs
    • 1
    • 2
  • Richard I. Shader
    • 1
    • 2
  1. 1.Division of Clinical Pharmacology, Departments of Psychiatry and MedicineTufts-New England Medical CenterBostonUSA
  2. 2.Medizinische Universitätsklinik, University of BonnGermany

Personalised recommendations